Kura Oncology, Inc.’s Post

Collaboration is the key to drug development. In The Medicine Maker’s recent article, our chief commercial officer Brian Powl shares his thoughts on efficient cross-collaboration, including involving various professional parties early on in the #drugdevelopment process to optimize each step along the way.      Read the full piece, including additional insights here: https://lnkd.in/g9bNdXZd  

Brandy Comyford

Driving Innovations in Preclinical Oncology and Immuno-Oncology Research

4w

This approach not only enhances efficiency but also drives innovation and better outcomes in the drug development journey. Great read!

To view or add a comment, sign in

Explore topics